Cero Therapeutics announces dose intensification in Phase 1 study of CER-1236

CERo Therapeutics (CERO) “announces it has administered a second dose in the second patient in the first cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia. The multi-dose intensification has been authorized by the study’s Institutional Review Board following review of initial pharmacokinetic data from the first two enrolled patients showing cell expansion and will effectively double the amount of cell product infused in each subject relative to the previous protocol approach.” Robert Sikorski, M.D., Ph.D., CERo’s Chief Medical Officer, noted, “The recent modification to our study will allow us to evaluate the feasibility and safety of administering multiple infusions of CER-1236 in patients with AML and to assess the implications of increased dosing in this Phase 1 study. We appreciate the collaboration of our study centers, IRB, and the FDA, and we look forward to monitoring outcomes from this second patient and proceeding toward enrollment of the third patient in the cohort.”